Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Dose-Escalation Pharmacokinetic and Pharmacodynamic Study of TG01 Tablets in Combination With Erlotinib in Non-Small Cell Lung Cancer Patients

NCT00569114 is registered in ClinicalTrials.gov with Tragara Pharmaceuticals, Inc. as lead sponsor.

NCT NCT00569114
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00569114 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Dose-Escalation Pharmacokinetic and Pharmacodynamic Study of TG01 Tablets in Combination With Erlotinib in Non-Small Cell Lung Cancer Patients
Lead sponsor
Tragara Pharmaceuticals, Inc.
Phase
Phase 1
Overall status
Completed
Start date
October 31, 2007
Completion date
November 30, 2009
Enrollment
45 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer